We conducted a phase 1 trial assessing safety and efficacy of prophylactic maintenance
therapy with venetoclax and azacitidine (Ven/Aza) for patients with high-risk myelodysplastic …

Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are usually associated
with poor outcomes, especially in high‐risk AML/MDS. Allogeneic hematopoietic stem cell …

Venetoclax and azacitidine (ven/aza) is our institutional preference for initial treatment of
non-core binding factor AML patients age≥ 60. Given potential durability of response in …

Introduction: Allogeneic SCT remains the only potentially curative therapy for acute leukemia
patients but with inferior outcomes for high-risk patients. Prior data on maintenance …

The oral histone deacetylase (HDAC) inhibitor (vorinostat) is safe and results in low
incidence of acute graft-versus-host disease (GVHD) after reduced-intensity conditioning …

Relapse is the most common cause of mortality in acute myeloid leukemia (AML) patients
after allogeneic stem cell transplant (SCT). Post-SCT maintenance strategies that prevent …

Background Venetoclax monotherapy is an effective option for patients with acute myeloid
leukemia (AML). Venetoclax has also been used in non-myeloablative conditioning …

Introduction Hypomethylating agents (HMAs), azacitidine (Aza) or decitabine, are standard
treatment (Tx) for patients (pts) with higher-risk myelodysplastic syndrome (HR-MDS) not …

Background: Acute myeloid leukemia (AML) is an aggressive malignancy and is the most
common and second most common form of acute leukemia in adults and children …

High-dose, posttransplantation cyclophosphamide (PTCy) reduces severe graft-versus-host
disease (GVHD) after allogeneic blood or marrow transplantation (alloBMT), but the impact …